Table 1.
Susceptibility rates and MIC values for Enterobacteriaceae collected from CA-UTI
| Country (n)/drug | CLSI/EUCAST | MIC50 | MIC90 | MIC range | ||
|---|---|---|---|---|---|---|
| % S | % I | % R | ||||
| Argentina (101) | ||||||
| Amoxicillin/clavulanic acid | 52.5/82.2 | 14.9/- | 32.7/17.8 | 8 | >32 | ≤1–>32 |
| Ceftibuten | 83.2/71.3 | 3.0/- | 13.9/28.7 | 0.25 | >16 | ≤0.06–>16 |
| Cefixime | 58.4/58.4 | 6.9/- | 34.7/41.6 | 0.5 | >8 | ≤0.12–>8 |
| Cefpodoxime | 56.4/53.5 | 5.0/- | 38.6/46.5 | 1 | >8 | ≤0.12–>8 |
| Cefuroxime | 43.6/50.5 | 13.9/- | 42.6/49.5 | 8 | >32 | ≤1–>32 |
| Cefaclor | 47.5/NA | 6.9/NA | 45.5/NA | 16 | >32 | ≤0.5–>32 |
| Ciprofloxacin | 50.5/49.5 | 49.5/1.0 | 0.0/49.5 | 1 | >1 | ≤0.002–>1 |
| Norfloxacin | 50.5/38.6 | 1.98/6.9 | 47.5/54.5 | 4 | >8 | 0.03–>8 |
| Fosfomycin | 91.1/84.2 | 1.0/- | 7.9/15.8 | 4 | 64 | ≤0.25–>128 |
| Nitrofurantoin | 51.5/64.4 (100)a | 12.9/- | 35.6/35.6 | 32 | >128 | ≤2–>128 |
| Trimethoprim/sulfamethoxazole | 49.5/49.5 | 0.0/1.0 | 50.5/49.5 | 4 | >64 | ≤0.5–>64 |
| Mexico (98) | ||||||
| Amoxicillin/clavulanic acid | 58.2/92.9 | 28.6/- | 13.3/7.1 | 8 | 32 | ≤1–>32 |
| Ceftibuten | 77.6/66.3 | 6.1/- | 16.3/33.7 | 0.25 | >16 | ≤0.06–>16 |
| Cefixime | 58.2/58.2 | 6.1/- | 35.7/41.8 | 0.5 | >8 | ≤0.12–>8 |
| Cefpodoxime | 60.2/54.1 | 3.1/- | 36.7/45.9 | 1 | >8 | ≤0.12–>8 |
| Cefuroxime | 43.9/58.2 | 16.3/- | 39.8/41.8 | 8 | >32 | ≤1–>32 |
| Cefaclor | 45.9/NA | 7.1/NA | 46.9/NA | 16 | >32 | ≤0.5–>32 |
| Ciprofloxacin | 51.0/45.9 | 50.0/5.1 | 0.0/49.0 | 1 | >1 | 0.004–>1 |
| Norfloxacin | 48.0/37.8 | 6.1/4.1 | 45.9/58.2 | 8 | >8 | 0.03–>8 |
| Fosfomycin | 95.9/90.8 | 1.0/- | 3.1/9.2 | 2 | 32 | ≤0.25–>128 |
| Nitrofurantoin | 65.3/80.6 (94.7)c | 15.3/- | 19.4/19.4 | 16 | >128 | ≤2–>128 |
| Trimethoprim/sulfamethoxazole | 30.6/30.6 | 0.0/3.1 | 69.4/66.3 | >64 | >64 | ≤0.5–>64 |
| Venezuela (95) | ||||||
| Amoxicillin/clavulanic acid | 55.8/88.4 | 26.3/- | 17.9/11.6 | 8 | >32 | ≤1–>32 |
| Ceftibuten | 89.5/84.2 | 2.1/- | 8.4/15.8 | 0.25 | 16 | ≤0.06–>16 |
| Cefixime | 74.7/74.7 | 8.4/- | 16.8/25.3 | 0.5 | >8 | ≤0.12–>8 |
| Cefpodoxime | 82.1/76.8 | 1.1/- | 16.8/23.2 | 0.5 | >8 | ≤0.12–>8 |
| Cefuroxime | 52.6/77.9 | 29.5/- | 17.9/22.1 | 4 | >32 | ≤1–>32 |
| Cefaclor | 64.2/NA | 6.3/NA | 29.5/NA | 4 | >32 | ≤0.5–>32 |
| Ciprofloxacin | 72.6/72.6 | 27.4/0.0 | 0.0/27.4 | 0.015 | >1 | ≤0.002–>1 |
| Norfloxacin | 72.6/63.2 | 0.0/4.2 | 27.4/32.6 | 0.12 | >8 | ≤0.015–>8 |
| Fosfomycin | 92.6/88.4 | 3.2/- | 4.2/11.6 | 2 | 64 | ≤0.25–>128 |
| Nitrofurantoin | 68.4/81.1 (97.0)c | 12.6/- | 19.0/19.0 | 16 | 128 | 4–>128 |
| Trimethoprim/sulfamethoxazole | 57.9/57.9 | 0.0/1.1 | 42.1/41.1 | ≤0.5 | >64 | ≤0.5–>64 |
| Russia (160) | ||||||
| Amoxicillin/clavulanic acid | 75.6/95.6 | 15.6/- | 8.8/4.4 | 4 | 16 | ≤1–>32 |
| Ceftibuten | 93.1/91.3 | 0.6/- | 6.3/8.7 | 0.12 | 1 | ≤0.06–>16 |
| Cefixime | 81.3/81.3 | 3.1/- | 15.6/18.7 | 0.5 | 8 | ≤0.12–>8 |
| Cefpodoxime | 81.9/80.0 | 1.2/- | 16.9/20.0 | 0.5 | >8 | ≤0.12–>8 |
| Cefuroxime | 63.7/79.4 | 16.9/- | 19.4/20.6 | 4 | >32 | ≤1–>32 |
| Cefaclor | 76.2/NA | 1.9/NA | 21.9/NA | 4 | >32 | ≤0.5–>32 |
| Ciprofloxacin | 80.0/79.4 | 20.0/0.6 | 0.0/20.0 | 0.015 | >1 | 0.004–>1 |
| Norfloxacin | 81.9/76.9 | 0.0/2.5 | 18.1/20.6 | 0.06 | >8 | 0.03–>8 |
| Fosfomycin | 98.1/95.6 | 0.6/- | 1.3/4.4 | 1 | 16 | ≤0.25–>128 |
| Nitrofurantoin | 83.8/91.9 (98.4)c | 8.1/- | 8.1/8.1 | 16 | 64 | ≤2–>128 |
| Trimethoprim/sulfamethoxazole | 75.6/75.6 | 0.0/0.6 | 24.4/23.8 | ≤0.5 | >64 | ≤0.5–>64 |
| Philippines (113) | ||||||
| Amoxicillin/clavulanic acid | 54.0/84.1 | 16.8/- | 29.2/15.9 | 8 | >32 | ≤1–>32 |
| Ceftibuten | 75.2/71.7 | 7.1/- | 17.7/28.3 | 0.12 | >16 | ≤0.06–>16 |
| Cefixime | 62.8/62.8 | 3.5/- | 33.6/37.2 | 0.5 | >8 | ≤0.12–>8 |
| Cefpodoxime | 67.3/62.8 | 2.7/- | 30.1/37.2 | 0.5 | >8 | ≤0.12–>8 |
| Cefuroxime | 48.7/59.3 | 16.8/- | 34.5/40.7 | 8 | >32 | ≤1–>32 |
| Cefaclor | 54.0/NA | 3.5/NA | 42.5/NA | 4 | >32 | ≤0.5–>32 |
| Ciprofloxacin | 62.0/59.3 | 38.1/2.7 | 0/38.1 | 0.12 | >1 | ≤0.002–>1 |
| Norfloxacin | 63.7/54.9 | 8.9/1.8 | 27.4/43.4 | 0.5 | >8 | ≤0.015–>8 |
| Fosfomycin | 91.2/83.2 | 3.5/- | 5.3/16.8 | 4 | 64.0 | ≤0.25–>128 |
| Nitrofurantoin | 53.1/73.5 (96.3)c | 20.4/- | 26.6/26.6 | 32 | 128.0 | ≤2–>128 |
| Trimethoprim/sulfamethoxazole | 44.3/44.3 | 0/1.8 | 55.8/54.0 | >64 | >64 | ≤0.5–>64 |
Number in parentheses is the susceptibility rates when applied to E. coli only (EUCAST recommendation)
CLSI Clinical Laboratory Standards Institute, EUCAST European Committee for Antimicrobial Susceptibility Testing, I intermediate, MIC Minimal inhibitory concentrations, R resistant, S susceptible, CA-UTI community-acquired urinary tract infection, NA or a dash = No interpretive breakpoints available